Protean agonism at alpha2A-adrenoceptors

Area of Science:

• Pharmacology
• Cell Biology
• Molecular Biology

Background:

• Alpha2A-adrenoceptors (α2A-ARs) are G protein-coupled receptors involved in various physiological processes.
• Understanding receptor-ligand interactions is crucial for developing targeted therapeutics.
• Human erythroleukemia (HEL) cells express endogenous α2A-ARs, making them a valuable model system.

Purpose of the Study:

• To investigate the coupling of endogenous α2A-ARs in HEL 92.1.7 cells to Ca2+ mobilization and cAMP production.
• To characterize the agonist and inverse agonist activities of medetomidine enantiomers at α2A-ARs.
• To explore the potential therapeutic implications of modulating α2A-AR constitutive activity.

Main Methods:

• Utilized human erythroleukemia (HEL 92.1.7) cells expressing endogenous alpha2A-adrenoceptors.
• Assessed calcium (Ca2+) mobilization and forskolin-stimulated cyclic adenosine monophosphate (cAMP) production.
• Tested the effects of dexmedetomidine, levomedetomidine, MPV-2088, and other alpha2-adrenergic ligands.

Main Results:

• Dexmedetomidine acted as an agonist, causing Ca2+ mobilization and inhibiting cAMP production.
• Levomedetomidine exhibited inverse agonist activity, reducing Ca2+ and increasing cAMP production.
• MPV-2088, a neutral ligand, antagonized responses to both dexmedetomidine and levomedetomidine.
• Some antagonists, like rauwolscine and idazoxan, displayed inverse agonist activity.
• Results suggest HEL 92.1.7 cells possess constitutively active, precoupled α2A-ARs.

Conclusions:

• HEL 92.1.7 cells exhibit constitutive α2A-adrenoceptor activity, modulated by pertussis toxin-sensitive G proteins.
• Levomedetomidine, a "protean agonist," can inhibit this constitutive activity, offering a novel therapeutic approach.
• Modulating inherent receptor "tone" presents a new therapeutic principle for receptor dysfunction disorders.